MD-6000S Bladder Scanner
MEDA Co., Ltd. · Decision date Sep 24, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on 2026-09-24 for K260313, a traditional 510(k) submitted by MEDA Co., Ltd. of Tianjin, CN, and received on 01/30/2026. The device is the MD-6000S Bladder Scanner, listed under device classification name System, Imaging, Pulsed Echo, Ultrasonic, regulation number 892.1560, product code IYO with subsequent product code ITX, in the Radiology specialty and review panel. The record states the review was not conducted by a third party and was not a combination product.
The FDA document describes the MD-6000S as a B-mode pulsed-echo ultrasound device intended to measure bladder volume, for use in medical and nursing care institutions by appropriately trained users. SESE means the submission was cleared as substantially equivalent; it is not a PMA approval. The record does not state the predicate device, the basis for the equivalence determination, or any performance data, so the clinical evidence behind the clearance remains unknown from these sources.
The listed documents also include unrelated search-result content, including a reference to a BioCon-1100 device, which is not described here as part of this clearance. No summary statement text was captured for K260313, and no labeling, indications beyond the quoted intent, or postmarket obligations can be confirmed from the available material.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Radiology
- Decision date
- Sep 24, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260313
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- MEDA Co., Ltd.
- Product code
- IYO
- Decision code
- SESE
- Decision date
- Sep 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Imaging, Pulsed Echo, Ultrasonic.
- Applicant
- MEDA Co., Ltd.
- Product code
- IYO
- FDA device class
- 2
FDA decision timeline
K260313 received
Application receipt date recorded by FDA.
K260313 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code IYO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Evident Vascular, Inc. | 510(k) clearance | Oct 28, 2026 | FDA | |
Accuro XVK262093 | Rivanna Medical, Inc. | 510(k) clearance | Oct 20, 2026 | FDA |
Lilium one (USM330)K260605 | Lilium Otsuka Co., Ltd. | 510(k) clearance | Oct 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
MEDA Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Tianjin
Sources and methodology
- Original FDA record: K260313
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

